Solvay

Weaker expectations for the oil & gas business

07/11/19 -"This led to an impairment (92% for goodwill) on the former Rhodia and Chemlogics activities (Novecare – Advance Formulations), which damaged the Q3 figures and came fully out of the blue. In ..."

PDF page sample
Pages
63
Language
English
Published on
07/11/19
Download
You may also be interested by these reports :
06/11/26
SGL Carbon reported a resilient performance in 9M26, with EBITDApre declining just 2% despite a 9% decline in sales, reflecting the benefits of ...
05/11/26
Q3 2026 growth was price-led, as contract resets lifted prices while volumes recovered only modestly from a weak base. Advanced Intermediates appears ...
05/11/26
Arkema saw largely weak demand across Europe and Asia, while the US improved. Growth in industrial adhesives, high-performance polymers, UV-curing ...
05/11/26
Lanxess’s Q3 2026 result is a mixed bag. Sales and adjusted EBITDA slightly beat street estimates; however, growth was price-led, reflecting cost ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO